FDA authorizes expanded use of Mounjaro to curb heart attacks and strokes
The FDA has broadened approval of Eli Lilly's diabetes drug Mounjaro, allowing it to be prescribed for preventing cardiovascular events in high-risk adults with type 2 diabetes.
The U.S. Food and Drug Administration has extended the label of Mounjaro, Eli Lilly's leading type 2 diabetes treatment, to include prevention of heart attacks and strokes in adults with diabetes who face high cardiovascular risk. This decision follows trial data showing Mounjaro cuts major cardiovascular events by an additional 8% relative to the older drug Trulicity. Lilly’s president of cardiometabolic health, Kenneth Custer, emphasized that the expansion leverages the drug’s strong track record in glycemic control and weight loss, and aligns it with GLP-1 medicines that already demonstrate heart benefits.
Mounjaro is also marketed for weight management under the name Zepbound, and the firm is investigating newer compounds that target multiple hormones. The approval offers clinicians a proven option to lower both diabetes-related and heart-related risks in a single medication.
Why it matters
The expanded approval gives doctors a proven diabetes drug that also reduces the risk of heart attacks and strokes.
In this story
